Nutra Pharma Corp (NPHC) EBITDA (2010 - 2026)

Nutra Pharma has disclosed EBITDA across 17 years of filings, most recently posting -$435464.0 for Q2 2026.

• In Q2 2026, EBITDA fell 49.89% year-over-year to -$435464.0; the TTM figure through Jun 2026 stood at -$1.6 million (down 63.02% YoY), while the FY2025 annual figure was -$1.5 million, down 66.47% from the prior year.
• EBITDA came in at -$435464.0 for Q2 2026 at Nutra Pharma, down from -$379249.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$140222.0 in Q4 2023 to a low of -$1.0 million in Q4 2022.
• Average EBITDA over 5 years is -$330547.5, with a median of -$301866.5 recorded in 2022.
• Year-over-year, EBITDA jumped 86.27% in 2023 and slumped 160.48% in 2025.
• Over 5 years, EBITDA stood at -$1.0 million in 2022, then surged by 86.27% to -$140222.0 in 2023, then dropped by 27.56% to -$178867.0 in 2024, then tumbled by 160.48% to -$465914.0 in 2025, then gained by 6.54% to -$435464.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$435464.0 in Q2 2026, -$379249.0 in Q1 2026, and -$465914.0 in Q4 2025.